Peptides as Next Growth Frontier for Hims & Hers as GLP-1 Business Evolves
Hims & Hers Health is pursuing peptides as a potential growth driver as its high‑margin compounded GLP‑1 business matures. The FDA plans a July 2026 review of peptides for possible inclusion on the 503A bulk list, a step that could enable regulated, physician‑led peptide therapy and unlock new revenue, though progress is not immediate and clinical evidence is limited. The company bought a peptide facility in 2025 and intends to steer users toward branded therapies rather than proprietary compounded GLP‑1 drugs.